Medpace Holdings, Inc. · Healthcare
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Healthcare
Medical - Diagnostics & Research
5,900
2016-08-11
1.39
Insider Activity
McCarthy Cornelius P. III
director
29 SH @ $0.00
2026-03-31
McCarthy Cornelius P. III
director
29 SH @ $0.00
2026-03-31
Kraft Robert O.
director
33 SH @ $0.00
2026-03-31
Kraft Robert O.
director
33 SH @ $0.00
2026-03-31
Carley Brian T
director
36 SH @ $0.00
2026-03-31
Carley Brian T
director
36 SH @ $0.00
2026-03-31
BURWIG SUSAN E
officer: Exec. VP, Operations
12,000 SH @ $166.73
2026-03-18
BURWIG SUSAN E
officer: Exec. VP, Operations
12,000 SH @ $166.73
2026-03-18

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Medpace To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Medpace between April 22, 2025 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 10, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Lead Plaintiff Deadline June 5, 2026 NEW YORK, April 10, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Medpace Holdings, Inc. ("Medpace" or the Company") (NASDAQ: MEDP) in the United States District Court for the Southern District of Ohio on behalf of all persons and entities who purchased or otherwise acquired Medpace common stock between April 22, 2025 and February 9, 2026, both dates inclusive (the "Class Period"). Investors have until June 5, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive (the “Class Period”). Medpace investors have until June 8, 2026 to file a lead plaintiff motion.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MEDPACE HOLDINGS, INC. (MEDP), CONTACT THE LAW OFFICES OF HOWARD G. SM.

LOS ANGELES--(BUSINESS WIRE)---- $STOCKS--Law Offices of Frank R. Cruz Encourages Medpace Holdings, Inc. (MEDP) Shareholders To Inquire About Securities Fraud Class Action.

New York, New York--(Newsfile Corp. - April 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Medpace Holdings, Inc. ("Medpace" or the "Company") (NASDAQ: MEDP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.